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Abstract Microparticles made from degradable polyhy-
droxyalkanoates of different chemical compositions a
homopolymer of 3-hydroxybutyric acid, copolymers of
3-hydroxybutyric and 4-hydroxybutyric acids (P3HB/4HB),
3-hydroxybutyric and 3-hydroxyvaleric acids (P3HB/3HV),
3-hydroxybutyric and 3-hydroxyhexanoic acids (P3HB/
3HHx) were prepared using the solvent evaporation tech-
nique, from double emulsions. The study addresses the
influence of the chemical compositions on the size and n-
potential of microparticles. P3HB microparticles loaded
with doxorubicin have been prepared and investigated. Their
average diameter and n-potential have been found to be
dependent upon the level of loading (1, 5, and 10 % of the
polymer mass). Investigation of the in vitro drug release
behavior showed that the total drug released from the
microparticle into the medium increased with mass con-
centration of the drug. In this study mouse fibroblast NIH
3T3 cells were cultivated on PHA microparticles, and results
of using fluorescent DAPI DNA stain, and MTT assay
showed that microparticles prepared from PHAs of different
chemical compositions did not exhibit cytotoxicity to cells
cultured on them and proved to be highly biocompatible. Cell
attachment and proliferation on PHA microparticles were
similar to those on polystyrene. The cytostatic drug encap-
sulated in P3HB/3HV microparticles has been proven to be
effective against HeLa tumor cells.
1 Introduction
Designing of controlled drug delivery systems (DDS) is a
promising and rapidly developing line of biotechnology
and experimental pharmacology. About 25 % of the drugs
sold in the world at the present time are administered via
transport/delivery systems [1].
DDS enable sustained release of the drugs, direct them
to a specific organ or tissue, enhance their bioavailability,
and reduce possible side effects of toxic drugs. It has
been generally accepted that the most promising drug
delivery systems are sustained-release DDS in the form
of micro- and nanoparticles, which can be administered
subcutaneously, intramuscularly, orally, and intravenously
[2, 3].
Prior to construction of micro- and nanoparticle DDS,
the properties of the biopolymers used in this process need
to be examined in detail. By varying the properties of
biopolymers, one can control the drug release rate. The
choice of the biopolymer and the drug should be based on
the knowledge of how they will interact and behave in the
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organism. Thus, a comprehensive approach is needed to
tackle the issue of drug delivery.
Among the wide range of biomaterials, a special
position is occupied by linear polyesters of microbial
origin, the so-called polyhydroxyalkanoates (PHAs). In
recent years, PHAs have been increasingly used as
materials to construct matrices for drug encapsulation and
delivery and for cell and tissue engineering. The main
advantage of PHAs is that they can consist of monomer
units with different carbon chain lengths, making up
polymers with different chemical structure. The most
popular and the best studied PHA is a homopolymer of
3-hydroxybutyric acid (P3HB). PHA copolymers are more
promising materials as their properties can vary within a
fairly broad range, depending upon the proportions of
different monomer units contained in them. The resulting
materials have different properties—from high-crystallinity
thermoplasts to construction elastomers [4–6]. There are,
however, very few published studies on the use of PHA
copolymers, whose synthesis is a complex technological
task, for the construction of special devices such as drug
micro-carriers.
By varying the parameters of the PHA matrix, one can
get the unique opportunity to control drug release
kinetics. Short-chain-length PHAs are degraded via sur-
face erosion, which makes this type of PHAs the most
attractive candidates for being used as drug carriers. The
main advantages of microparticles based on short-chain-
length PHAs are their crystallinity, hydrophobicity, and
the presence of pores on their surface, which provides
the most effective drug release from the degrading matrix
[7].
At the present time, PHAs are used to prepare micro-
particles loaded with analgesics [8] and anti-inflammatory
drugs; their release kinetics has been studied quite well [9–
12]. PHA microparticles, films, and 3D matrices are
promising carriers for antibiotics, enabling the sustained
release of the drug [13–16]. Incorporation of protein
compounds in composite microparticles consisting of
PHAs and polyethylene glycol and polylactides was
reported by Lionzo et al. [9].
Investigations performed at the Institute of Biophysics,
Siberian Branch, Russian Academy of Sciences, revealed
the high biocompatibility of high purity PHA samples at
cellular and tissue levels, including contact with blood, as
well as their applicability for the design of endoprostheses
of various kinds, as matrices of functioning cells, and for
deposition of drugs [17, 18].
The goal of this study was to compare polymer micro-
particles prepared from PHAs with different chemical
composition and to investigate their biocompatibility and
drug effectiveness in vitro.
2 Materials and methods
2.1 Materials
High-purity PHA specimens—a homopolymer of
3-hydroxybutyric acid (P3HB) and 3-hydroxybutyric/4-
hydroxybutyric acid (P3HB/4HB), 3-hydroxybutyric/3-
hydroxyvaleric acid (P3HB/3HV) and 3-hydroxybutyric/3-
hydroxyhexanoic acid (P3HB/3HHx) copolymers were
produced in the Institute of Biophysics SB RAS by culti-
vation hydrogen-oxidizing microorganisms (Table 1). The
specimens were subjected to methanolysis, and PHA con-
centration and composition were analyzed by determining
fatty acid methyl esters with a GCD plus gas chromato-
graph-mass spectrometer (Hewlett Packard, USA).
X-ray structure analysis and crystallinity determination
of PHA samples were performed using a D8 ADVANCE
X-ray spectrometer (Bruker, Germany) (graphite mono-
chromator on a reflected beam). Spectra were taken in a
scan-step mode, with a 0.04 step and exposure time 2 s, to
measure intensity at point. The instrument was operating at
40 kV 9 40 lA.
Molecular weight and molecular-weight distribution of
PHAs were examined using a gel permeation chromato-
graph (‘‘Agilent Technologies’’ 1260 Infinity, USA) rela-
tive to reference polystyrenes from Fluka (Switzerland,
Germany). The calculated parameters included the number
average molecular weight (Mn), the weight average
molecular weight (Mw), and polydispersity (PD = Mw/
Mn), which provides an estimate of the proportions of
fragments with different polymerization abilities in the
polymer.
2.2 Preparation of microparticles
Microparticles were prepared by the solvent evaporation
technique, using double (water/oil) emulsions. The double
emulsion contained 0.4 g PHA in 10 ml of dichlorometh-
ane and 100 ml 0.5 % (w/v) PVA. The resulting double
emulsion was mechanically agitated at 24,000 rpm (IKA
Ultra-Turrax T25 digital high-performance homogenizer
(Germany) until the solvent had completely evaporated.
All emulsions were continuously mixed mechanically for
24 h, until the solvent had completely evaporated. Micro-
particles were collected by centrifuging (at 10,000 rpm, for
5 min), rinsed 6 times in distilled water, and lyophilic dryer
in an Alpha 1–2 LD plus (Christ, Germany).
The yield of microparticles was calculated as percent of
the mass of the polymer used to prepare them:
Y ¼ Mp  100%
Mm
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where Mm is the mass of the prepared microparticles (mg)
and Mp is the mass of the total polymer used for prepara-
tion of microparticles (mg).
The morphology of the particles was analyzed using an
FEI Company Quanta 20 scanning electron microscope
(USA). The size and size distributions of microspheres
were determined using Zetasizer Nano ZS (Malvern, UK).
Each sample was measured in triplicate. The obtained size
distribution and mean diameters were used to describe the
particle size. The surface charge of the microparticles was
characterized in terms of zeta potential, which was
determined the electrophoretic mobility and then applying
the Henry equation using Zetasizer Nano ZS (Malvern,
UK).
2.3 Preparation of drug-loaded polymer microparticles
Microparticles loaded with doxorubicin (DOX) were pre-
pared using the solvent evaporation technique from the
double emulsion. The DOX (4, 20 or 40 mg) was dissolved
in 10 ml of dichloromethane containing 0.4 g P3HB or
P3HB/3HV (6.5 mol%). Aqueous phase as a dispersion
medium for the microparticles production was prepared by
using 100 ml of a 0.5 % (w/v) PVA aqueous solution. The
emulsion was agitated at 24,000 rpm (IKA Ultra-Turrax
T25 digital high-performance homogenizer (Germany)
until the solvent had completely evaporated. Microparticles
were collected by centrifuging (at 10,000 rpm, for 5 min),
rinsed six times in distilled water, and freeze dried in an
LS-500 lyophilic dryer (Russia).
The amount of the drug loaded into the polymer matrix
was determined spectrophotometrically (Uvicon 943,
Italy), by measuring its initial and residual concentrations
in the emulsion.
The encapsulation efficiency (E) was calculated using
the following formula:
E ¼ Minit  100%
Menc
where Menc is the mass of the encapsulated drug in the
polymer matrix (mg) and Minit is the mass of the initial
amount of drug (mg).
2.4 In vitro drug release behavior
Drug-loaded PHA microparticles were sterilized using UV
radiation for 20 min and then placed in sterile centrifuge tubes
with caps, containing 5 ml of phosphate-buffered saline (PBS,
pH 7.3); the tubes were incubated at 37 C (n = 3). Micro-
particles were settled by centrifugation (for 5 min at
10,000 rpm), and samples were taken to determine the amount
of the drug released into PBS using a Uvicon 943 spectro-
photometer (Italy), based on absorption maxima at 580 nm.
Drug release (DR) into PBS was determined as follows:
DR ¼ r  100%
e
Table 1 Biodegradable PHAs of different chemical compositions used microparticles for preparation
Polymer composition (mol%) Structural formula Polymer properties
Mn (kDa) Mw (kDa) PD
P3HB
100
710 1,200 1.71
P3HB/3HV
93.5/6.5
890 1,700 1.91
P3HB/3HV
89.5/10.5
840 1,500 1.79
P3HB/3HV
80/20
663 1,500 2.27
P3HB/3HV
63/37
1,026 2,000 2.00
P3HB/4HHx
93/7
270 950 3.52
P3HB/4HB
93.9/6.1
140 410 2.93
P3HB/4HB
84/16
370 970 2.62
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where e is the amount of the encapsulated drug (mg/mg)
and r is released drug (mg/mg).
Theoretical analysis of the experimental data on drug
release and quantification of the value of the drug diffusion
coefficient in the polymer phase was performed through
the graphic solution of the equations in coordinates
(mt/m?) - (t)
0.5 and in semilogarithmic coordinates
ln(1 - mt/m?) as described elsewhere [19, 20].
2.5 Cell cultivation
Determination of possible toxicity of PHA microparticles
were investigated in experiments with mouse fibroblast NIH
3T3 cells, which were seeded onto microparticles
(5 9 103 cells/cm2) placed in 24-well plates, in accordance
with the estimation as described Nakoaka R. [21]. To
estimate influence the composition of the particles have,
suspensions of the particles in PBS was prepared with the
concentration 2 mg/ml; 100 ll of suspension of the parti-
cles of each type were put into 24-well culture plates
(Cellstar, Greiner bio-one). The microparticles were steril-
ized using H2O2 plasma in a Sterrad NX sterilization system
(Johnson&Johnson, USA) or autoclaving at 1 atm. Poly-
styrene plates (Orange Scientific) were used as controls.
Fibroblasts were cultured in Dulbecco’s Minimal Eagle
Medium (DMEM) supplemented with fetal bovine serum
(10 % v/v) and a solution of antibiotics (streptomycin 100 lg/
ml, penicillin 100 IU/ml) (Gibco, Invitrogen) in a CO2 incu-
bator with CO2 level maintained at 5 %, at a temperature of
37 C. The medium was replaced every three days.
Analysis of cell morphology and cell counting were
performed in 1, 4, and 7 days after seeding on micropar-
ticles, using fluorescent stain DAPI (Sigma); cells were
counted using an Axiovert 40 fluorescence microscope
Fig. 1 SEM images of the
microparticles prepared from
PHAs of different chemical
compositions: a poly-3-
hydroxybutyrate, b poly-3-
hydroxybutyrate-co-3-
hydroxyvalerate (6.5 mol%),
c poly-3-hydroxybutyrate-co-3-
hydroxyvalerate (37 mol%),
d poly-3-hydroxybutyrate-co-3-
hydroxyhexanoate (7 mol%),
e poly-3-hydroxybutyrate-co-4-
hydroxybutyrate (6.1 mol%),
f poly-3-hydroxybutyrate-co-4-
hydroxybutyrate (16 mol%).
The bar 5 lm
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(Carl Zeiss). Viability of cultured fibroblast NIH 3T3 cells
was evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) (Sigma) assay.
Viability evaluation was based on the ability of dehydro-
genases of living cells to reduce 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl tetrazolium bromide to formazan, which
characterizes mitochondrial activity, estimates the abun-
dance of living cells, and indirectly indicates the ability of
cells to proliferate on the matrices. MTT solution (50 ll)
and complete nutrient medium (950 ll) were added to each
well containing a polymer. After 3.5 h incubation, the
medium and MTT were replaced by DMSO to dissolve
MTT-formazan crystals. After 30 min, the supernatant was
transferred to the 96-well plate, and optical density was
measured at wavelength 540 nm, using a Bio-Rad 680
microplate reader (Bio-Rad Laboratories Inc, USA). The
number of cells was determined from the calibration graph.
2.6 Cytotoxicity of DOX-loaded PHA microparticles
For the experiment the polymer particles from P3HB/3HV
(6.5 mol%) of 0.2 and 1.2 microns with various drug
loading were prepared. Loading of the particles with the
drug was done in such a way, that during introduction of
the particles in the culture in the form of suspension the
concentrations were as follows: 0.6; 3.2; 6.0 lg/ml.
Microparticles of mean diameters 0.2 and 1.1 lm were
prepared using 1.2-lm and 0.25-lm-pore-size nitrocellu-
lose membrane filters (Sartorius).
The cytostatic effect of microparticles loaded with DOX
was estimated by the culture of tumor cells—HeLa. HeLa
line cells were put into the cell culture on the basis
10 9 103 cells/well. The medium RPMI ? FBS (10 %) ?
antibiotic (1 %) (streptomycin 100 lg/ml, penicillin 100 U/ml
(Gibco, Invitrogen)). Suspension of sterile particles (2 mg of
particles/200 ll of phosphate buffer) was introduced into each
well of 24-well plate. Cultivation was done by the standard
method in the humid medium during 3 days. Viability of cells
was tested daily in MTT assay in relation to the positive ref-
erence (free DOX was introduced into the cells culture in the
similar concentration: 0.6, 3.2 and 6.0 lg/ml).
2.7 Statistics
The results were analyzed statistically using the standard
software package of Microsoft Excel and the StatPlus
software. Arithmetic means, mean square error, and error
of the arithmetic mean were calculated in all cases. Sig-
nificant differences in average values were tested using the
Mann–Whitney U test (significance level: P = 0.05).
3 Results and discussion
3.1 Characterization of PHAs used to prepare
microparticles
Differences in the basic physical properties of the polymers
under study (Table 1) influenced the characteristics of the
microparticles. SEM images of the surface microstructure
of microparticles prepared from PHAs that differed in their
chemical composition and physicochemical properties
showed certain dissimilarities (Fig. 1).
Whatever the PHA composition, microparticles were
heterogeneous in their shape, and their surface structures
were different. Microparticles prepared from P3HB and
P3HB/3HV containing the lowest molar fraction of 3HV
(6.5 %) were practically smooth and of a regular spherical
shape, without surface deformation. Microparticles pre-
pared from P3HB/3HV with a high molar fraction of 3HV
(37 %) and P3HB/4HB (16 % 4HB) had a rough surface;
some of the particles were irregularly shaped. Visual esti-
mation showed that P3HB/4HB microparticles were of
larger size. Microparticles prepared from P3HB/3HHx
Fig. 2 Mean diameter and a n-potential b of the microparticles prepared
from PHAs of different chemical compositions: 1 poly-3-hydroxybuty-
rate, 2 poly-3-hydroxybutyrate-co-3-hydroxyvalerate (6.5 mol%), 3 poly-
3-hydroxybutyrate-co-3-hydroxyvalerate (10.5 mol%), 4 poly-3-hydro-
xybutyrate-co-3-hydroxyvalerate (20 mol%), 5 poly-3-hydroxybutyrate-
co-3-hydroxyvalerate (37 mol%), 6 poly-3-hydroxybutyrate-co-3-
hydroxyhexanoate (7 mol%), 7 poly-3-hydroxybutyrate-co-4-hydroxy-
butyrate (6.1 mol%), 8 poly-3-hydroxybutyrate-co-4-hydroxybutyrate
(16 mol%)
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(7 mol% HHx) and P3HB/4HB (6.1 mol% 4HB) had a
spherical shape and smooth surface.
Important parameters determining the tissue specificity
of the particles and their ability to cross biological barriers
are their size and size distribution. Nanoparticles generally
vary in size from 10 to 1,000 nm [22]. Microparticulated
drug delivery systems of bigger size are very promising
with various methods of administration: peroral (osmotic
minipumps), parenteral (nanoparticles and nanocapsules),
subcutaneous (implants), intracavitary (intrauterine inserts
and various suppositoria), buccal, etc. [23].
The average diameter of microparticles prepared from
PHA copolymers was larger than that of the particles
prepared from the homopolymer (Fig. 2a) although the
matrices prepared from P3HB/3HV (10 mol% 3HV) and
those prepared from 3HB were similarly sized, and their
average diameter was about 750–700 nm. The average
diameter of microparticles prepared from the P3HB/3HV
with the molar fraction of 3HV amounting to 37 % was
almost twice greater, reaching 1.25 lm. The average
diameter of P3HB/3HHx particles did not differ signifi-
cantly from that of P3HB/3HV (37 mol% 3HV) ones:
1.14 lm. Microparticles prepared from P3HB/4HB con-
taining 6.1 and 16 mol% 4HB were significantly larger
than other copolymer microparticles, and their diameters
were 2.3 and 2.6 lm, respectively (Fig. 2a).
Another important parameter is n-potential of micro-
particles, which characterizes stability or coagulation of the
particles in the dispersion medium [24].
Determination of the zeta potential of microparticles
prepared from PHAs with different chemical composition
gave the following results (Fig 2b): the lowest n-potential
was recorded for P3HB/3HHx microparticles (-32.2 mV);
the second-lowest values of this parameter were recorded for
P3HB/4HB (about -29–27 mV). P3HB microparticles had
the highest n-potential (about -11 mV). Microparticles
prepared from P3HB/3HV with different molar fractions of
3HV had a lower n-potential, which varied from -23 to
-26 mV and was not influenced by the molar fraction of
3HV.
3.2 Biocompatibility and adhesive properties of PHA
microparticles in vitro
Figure 3 shows results of MTT assay: determination of
viability of cells cultured in the presence of PHA micro-
particles treated with H2O2 plasma or by autoclaving on
direct contact with fibroblast NIH 3T3 cells.
At 3 d after seeding, counts of attached cells showed
that the number of cells on microparticles treated with
H2O2 plasma was higher. The largest number of cells (up to
28–33 in the field of view) were attached to microparticles
prepared from P3HB and P3HB/3HV with 20 mol% 3HV.
That number was 1.4–1.8 times higher than the number of
cells attached to the microparticles sterilized by autoclav-
ing (Fig. 3). The number of cells attached to autoclaved
microparticles prepared from P3HB/3HV (6.5, 10 and
37 mol% 3HV), P3HB/3HHx, and P3HB/4HB (6.1 and
16 mol% 4HB) was half that recorded on the correspond-
ing microparticles treated with H2O2 plasma.
A possible explanation for this might be that treatment
of polymer devices by physical methods (laser cutting or
plasma) strengthens interphase adhesion joints, increasing
surface hydrophilicity and, hence, improving its adhesion
properties.
MTT assay did not reveal any cytotoxic effect of auto-
claved or plasma-treated PHA microparticles. The number
of viable cells adhering to the surface of the matrices
treated with H2O2 plasma was higher than on the surface of
the autoclaved ones in all treatments (Fig. 3).
Results of the cell counts obtained using the fluorescent
DAPI DNA stain were as follows: at 3 d after fibroblast
NIH 3T3 cells were seeded onto microparticles, the number
of cells on PHA microparticles treated with H2O2 plasma
was significantly higher than on autoclaved ones (Fig. 4).
On plasma treated microparticles prepared from PHAs
with different chemical composition, cells spread well and
formed a monolayer. On the corresponding PHA micro-
particles sterilized by autoclaving, the number of cells was
1.5–2 times lower, and they showed an irregular shape.
As differences in the number of cells proliferating on
microparticles prepared from PHAs of different types are
insignificant, all of the polymers investigated in this study
are of good quality, showing high biocompatibility.
3.3 Preparation and investigation of DOX-loaded
microparticles
Conditions of loading drugs (doxorubicin, DOX) into
P3HB and P3HB/3HV (6.5 mol% 3HV) microparticles
Fig. 3 Amount of cells adhered to the microparticles surface 3 h
after seeding (numbers as in Fig. 2). Reference—polystyrene
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were developed and investigated. The average diameter of
the particles loaded with DOX was slightly, by 1.2 times,
increased, whatever the composition of the particles
(Fig. 5a).
The loading of DOX into P3HB/3HV (6.5 mol% 3HV)
microparticles did not alter their surface structure. The
DOX-loaded microparticles were of regular spherical shape
and had a smooth surface.
The relationship between the DOX load and n-potential
was studied using P3HB and P3HB/3HV (6.5 mol% 3HV)
microparticles (Fig. 5b). In both cases, the values of n-
potential of the drug-loaded particles were lower than those
of the unloaded ones, and more pronounced decrease in this
value was recorded for P3HB particles, whose n-potential
decreased 1.8 times.
As P3HB/3HV (6.5 mol% 3HV) microparticles had a
rather low n-potential, they were chosen for the further
study, in which DOX-loaded particles were used to
investigate their drug effectiveness.
DOX release kinetics was studied and found to be
dependent upon the level of loading (Fig. 6).
The larger the amount of the DOX entrapped in the
particles, the more that was released from P3HB/3HV
microparticles. Independently of the extent of the load with
the stain the curves had a typical 2-phase character—rapid
drug release for short time periods and long segments with
a nearly constant release rate. The initial output was more
likely connected with solving and washing out of the drug
from the microparticles’ surface. In the first 12 h the
release made 13.5 ± 1.4 and 8.9 ± 0.7 %, respectively,
under the maximum and minimum loads of the micropar-
ticles. Then, for the following 5 days (120 h), DOX release
rate increased dramatically, reaching 6.1 ± 0.6 and
8.92 ± 0.4 %, for microparticles that contained 1, 5, and
Fig. 4 DAPI staining of fibroblast NIH 3T3 cells on microparticles of
different types sterilized with autoclaving (a) andH2O2 plasma (b), 7 days
after seeding: P3HB poly-3-hydroxybutyrate, P3HB/3HV (6.5 mol%)
poly-3-hydroxybutyrate-co-3-hydroxyvalerate (6.5 mol%), P3HB/3HV
(37 mol%) poly-3-hydroxybutyrate-co-3-hydroxyvalerate (37 mol%),
P3HB/3HHx (7 mol%) poly-3-hydroxybutyrate-co-3-hydroxyhexanoate
(7 mol%), P3HB/4HB (6.1 mol%) poly-3-hydroxybutyrate-co-4-hydro-
xybutyrate (6.1 mol%), P3HB/4HB (16 mol%) poly-3-hydroxybutyrate-
co-4-hydroxybutyrate (16 mol%)
Fig. 5 Mean diameter and a n-
potential b of the microparticles
prepared from poly-3-
hydroxybutyrate (P3HB) and
poly-3-hydroxybutyrate-co-3-
hydroxyvalerate 6.5 mol%
(P3HB/3HV 6.5 mol%) after
loading different concentrations
of drugs: 1 P3HB, without drug;
2 P3HB, 1 % loaded drug; 3
P3HB; 5 % loaded drug, 4
P3HB, 10 % loaded drug; 5
P3HB/3HV 6.5 mol%, 5 %
loaded drug
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10 % DOX. The DOX release from microparticles was
gradual; during 528 h of the experiment the following
content of the drug in the environment was registered:
23.61 ± 1.9, 28.15 ± 1.8, and 34.6 ± 2.3 %, respectively,
with the initial load of the microparticles 1, 5, and 10 %.
Drug release kinetics from PHA microparticles can be
described by diffusion-kinetic equations that were pro-
posed by Livshits and coauthors [19] and Goreva and
coauthors [20].
The graphic solution of the equations in coordinates
mt=m1ð Þ  tð Þ0:5 ð1Þ
and in semilogarithmic coordinates
ln 1  mt=m1ð Þ ð2Þ
yielded quantification value of the drug diffusion coeffi-
cient in the polymer phase. Table 2 gives DOX diffusion
coefficients in P3HB/3HV (6.5 mol% 3HV) microparticles.
These results suggest a clear relationship between diffusion
coefficients and the drug loading in the microparticles.
In the first phase, diffusion coefficient is 2 and 9 times
higher for the microparticles with the greatest drug loading
than for the microparticles with lower loading—5 and
10 % of the initial DOX content of the microparticles,
respectively (Table 2, Eq. 1). In the second phase (when
the curve reaches a plateau), diffusion coefficient drops by
an order of magnitude, whatever DOX content of the
microparticles.
In the first phase, drug release occurs due to the classical
diffusion process. The linear phase of antibiotic release is
recorded simultaneously with diffusion. Slopes of linear
segments are close to each other and correspond to the
constant of hydrolytic degradation of P3HB/3HV. These
results prove that drug release from P3HB/3HV micro-
particles occurs due to the classical diffusion process.
3.4 An in vitro study of the inhibiting effect of DOX-
loaded microparticles
Figure 7 shows results of evaluation of the inhibiting effect
produced by DOX-loaded microparticles on HeLa cell
culture versus the effect of the free drug (Fig. 8).
At implementation of smaller particles (0.2 microns)
with the highest load (0.6 lg/ml) the effect of the cytostatic
drug depositing is comparable with free form as by the time
of beginning of the action, so by the inhibiting effect on the
cells. Particles loaded with the medium and lowest con-
centration (3.2 and 6.0 lg/ml) inhibited the growth of
tumor cells only by the 3rd day of the experiment com-
parable with free DOX, but the beginning of the drug’s
action was late in time; the maximum inhibiting effect was
observed on the 4th day. This is connected with the kinetics
of the drug outflow from the polymer matrix into the cul-
ture at which in the first 2 days the release of the drug in
the culture was low (at the level 0.09 and 0.07 lg/ml for
the highest and the lowest concentration of DOX, corre-
spondingly) and this concentration was insignificant for
suppression of HeLa growth.
At implementation of larger polymer particles the effect
of DOX depositing was more expressed (Fig. 7b). Delay in
the inhibiting effect was registered only on the first day and
only for the lowest and medium concentration of DOX
(correspondingly, concentration of DOX in the culture
made 0.08 and 0.28 lg/ml). Nevertheless, already on the
second day the cytostatic effect of the deposited DOX was
comparable with the action of the free drug.
These findings demonstrated the efficiency of the cyto-
static drug deposited in the microparticles constructed from
resorbing polymers in relation to the culure of HeLa tumor
cells.
4 Discussion
In this study, for the first time, microparticles were pre-
pared from four types of PHAs, containing different frac-
tions of 3HV, 4HB, and 3HHx monomer units, and their
Fig. 6 Dynamics of DOX release from poly-3-hydroxybutyrate-co-3-
hydroxyvalerate (6.5 mol%) microparticles with different levels of
antibiotic loading
Table 2 Diffusion coefficients of DOX in P3HB/3HV (3HV
6.5 mol%) microparticles determining the initial and final stages of
the diffusion process
Amount of encapsulated
of DOX (%)
Diffusion coefficients D 9 10-4 (cm/s)
At initial
stage
At final
stage
1 2.5 0.008
5 9.9 0.026
10 22.6 0.075
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comparative investigation was carried out. The studies
reported in the available literature described PHA micro-
particles prepared from one or two types of PHAs, without
discussing the effect of the chemical composition of the
polymer on the properties of microparticles. The polymers
used to prepare microparticles in those studies were P3HB/
3HV with a low molar fraction of 3HV (6–15 %) [25–27];
P3HB/3HV containing 5 mol% 3HV and PHB3/HHx with
12 mol% 3HHx [28]; P3HB/3HV (12 and 33 mol% 3HV)
and P3HB/4HB (6 and 20 mol% 4HB) with mPEG [29].
The present study revealed a significant effect of the
chemical composition of the polymer on the average
diameter and n-potential of microparticles. For instance,
the surface of the particles prepared from copolymers with
increased molar fractions of 3HV and 4HB was rougher
and their average diameter was 1.7–2.5 times greater than
that of P3HB particles.
There are very few literature data on n-potential of PHA
microparticles. This study showed that the values of n-
potential of microparticles prepared from different types of
PHAs varied significantly. The lowest values of n-potential
were recorded for PHB3/HHx microparticles (-32.2 mV)
and the n-potential of P3HB was no higher than -11 mV.
An important part of this study is comparative evalua-
tion of biocompatibility and adhesive properties of micro-
particles sterilized by different methods. MTT assay
performed to determine viability of cells cultured in the
presence of PHA microparticles did not show any toxic
effect of PHA microparticles treated by autoclaving or with
H2O2 plasma on direct contact with fibroblast NIH 3T3
cells. The number of viable cells adhering to the surface of
the matrices treated with H2O2 plasma was higher than on
the surface of the autoclaved ones in all treatments. Results
of MTT assay and cell counts using the fluorescent DAPI
DNA stain showed that microparticles prepared from PHAs
of different chemical compositions and sterilized by auto-
claving or with H2O2 plasma did not exhibit any cytotox-
icity. These results are in good agreement with the data
reported in the studies that evaluated biocompatibility of
microparticles in NIH/3T3 cell cultures, in which micro-
particles were prepared from P3HB and copolymers P3HB/
3HV (5 mol% 3HV) and P3HB/3HHx (12 mol% 3HHx)
[28] and amphiphilic nanoparticles with mPEG were pre-
pared from P3HB/3HV (33 mol% 3HV) and P3HB/4HB
(20 mol% 3HHx) [29].
This study was the first to reveal the effect of loading
P3HB and P3HB/3HV (6.5 mol% 3HV) microparticles
with doxorubicin on the n-potential of microparticles. The
n-potential of P3HB microparticles loaded with DOX (1, 5,
and 10 % of the polymer mass) was lower than that of the
Fig. 7 MTT assay: the effect of
DOX encapsulated in 0.2 lm
(a) and 1.2 lm (b) polymer
microparticles on the number of
viable cells in HeLa cell culture
Fig. 8 The effect of free DOX concentration on the number of viable
cells in HeLa cell culture: negative control, drug-free culture (DOX
concentration)—0.6, 3.2, 6 lg/ml
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unloaded microparticles. Similar results were obtained for
copolymer microparticles. Thus, DOX loading had a
favorable effect on this parameter of the particles. Different
levels of DOX loading also changed the average diameter
of microparticles.
Studies published in the past few years suggest high
potential of polymer microsystems for the delivery of
drugs, including doxorubicin [30–32]. The formulations
described in those studies include polymer micro- and
nanoparticles, doxorubicin-polypeptide conjugates for
thermally targeted delivery, polymer micelles with ionic
crosslinking for conjugation with the drug, micelles, etc.
[33–35].
The present study showed that doxorubicin was released
from the microparticles without any burst effect. The study
of DOX release kinetics as dependent upon the drug con-
tent of the matrix of microparticles showed that drug
release rate became almost 1.5 times faster as DOX content
of the matrix of microparticles was increased from 1 to
10 %. The results obtained in this study compare well with
the data on the release kinetics of gentamicin from P3HB/
3HV microparticles [36]; tramadol, piroxicam, and ibu-
profen from P3HB microparticles [8, 10, 11].
The cytostatic effect of P3HB/3HV (6.5 mol% 3HV)
microparticles loaded with DOX was estimated in the
culture of tumor cells—HeLa, using microparticles with
diameters 0.2 and 1.2 lm, containing 0.6, 3.2 and 6 lg/ml
DOX. The use of the larger-sized particles resulted in a
more pronounced effect of DOX. At day 3, however, the
cytostatic effect of the drug embedded in the particles was
comparable with the effect of free DOX.
5 Conclusion
Microparticles were prepared from different types of
PHAs. The experiments showed that by varying the
chemical composition of PHAs, one can prepare micro-
particles with different properties, which would be suitable
for drug loading. The average diameter and n-potential of
microparticles were found to be dependent on the level of
loading (1, 5, and 10 % of the polymer mass). None of the
high-purity PHAs directly contacting with NIH 3T3
fibroblast cells caused any toxic effect or impaired viability
of these cells, i.e. all PHAs used in this study are bio-
compatible and suitable for biomedical use. The effec-
tiveness of the cytostatic drug embedded in P3HB/3HV
(6.5 mol% 3HV) microparticles was proved in the culture
of tumor cells—HeLa. Results of the study provided a basis
for experiments on animals.
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